Interim Report January- March 2013

  · Net sales for the quarter amounted to SEK 26.8 million (30.0). Sales were
impacted by a negative currency effect of SEK 1.0 million compared to the same
period last year.
  · Operating income (EBIT) for the quarter was SEK 2.0 million (3.0), with
currency effects having a negative impact of SEK 1.0 million compared to the
same period last year.
  · Operating margin for the quarter was 7 percent (10).
  · Loss after tax for the quarter was SEK 0.1 million (-0.4).
  · Earnings per share for the quarter, basic and diluted were SEK 0.00 (0.00).

Significant events in the first quarter

  · Allenex subsidiary AbSorber received an EU grand of EUR 215,000 over a three
-year period.
  · Allenex received a breakthrough order in the U.S. for SBT Resolver™ from a
leading HLA typing laboratory. The yearly sales value is estimated at more than
SEK 2 million.

Significant events after the period end

  · Refinancing of all Allenex loans

Allenex president and CEO Anders Karlsson’s commentary on the first quarter
2013:

“Allenex continues to the launch of SBT Resolver™ for sequence based typing from
our Australian partner Conexio Genomics, which is a key part of the company’s
long-term growth strategy. Our geographic expansion of typing products from
Olerup SSP to new markets also continues, with product registration processes
now at final stages in key markets where our products are not yet available. The
first quarter 2013 shows lower sales that last year. At the same time it can be
noted that the strong Swedish krona has affected sales negatively compared to
last year, while the opening quarter in 2012 was a very strong quarter. After
the end of the reporting period, we also secured the refinancing of company
loans”.

For more information please contact:

Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail:
 (anders.karlsson@allenex.se)anders.karlsson@allenex.se
Yvonne Axelsson, CFO Allenex AB, and ph.: +468-50893972, e-mail:
yvonne.axelsson@allenex.se (yvonne.axelsson@allenex.se) (anders.karlsson@allenex
. 
se)

Allenex AB discloses the information provided herein pursuant to the Securities
Markets Act and /or the Financial Instruments Trading Act. The information was
submitted for publication on April 25, 2013, at 08.45 CET. Allenex is a life
science-company that develops, manufacture, market and sell products for safer
transplants of organs and bone marrow on the global market. Allenex is listed on
NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 54 persons are employed in the
Allenex group.